With Losses Mounting, MabVax Therapeutics Looks to Sell Off Assets

MabVax Therapeutics says it doesn?t have enough money to continue funding its operations. The San Diego biotech company, which is testing an antibody discovery platform intended to speed products to patients with cancer and pancreatitis, said Thursday it has retained a local investment banking firm, Objective Capital Partners, to guide its sale. As of Sept. [?]